New Drugs for Idiopathic Pulmonary Fibrosis: 2015 Top 10 Medical Innovation (VIDEO)
Nearly 80,000 American adults with idiopathic pulmonary fibrosis may breathe easier in 2015 with the recent FDA-approval of two new experimental drugs. Pirfenidone and nintedanib slow the disease progress of the lethal lung disease, which causes scarring of the air sacs. Prior to these developments, there was no known treatment for IPF, where life expectancy after diagnosis is just 3 to 5 years.
This video is part of the Idiopathic Pulmonary Fibrosis (IPF) Resource Center
Video provided by: YouTube